The REST Gene Signature Predicts Drug Sensitivity in Neuroblastoma Cell Lines and is Significantly Associated with Neuroblastoma Tumor Stage

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2014 Jun 27

PMID 24968265

Citations 19

Authors

Jianfeng Liang

Pan Tong

Wanni Zhao

Yaqiao Li

Li Zhang

Ying Xia

Yanbing Yu

Affiliations

Soon will be listed here.

Abstract

Neuroblastoma is the most common and deadly solid tumor in children, and there is currently no effective treatment available for neuroblastoma patients. The repressor element-1 silencing transcription (REST) factor has been found to play important roles in the regulation of neural differentiation and tumorigenesis. Recently, a REST signature consisting of downstream targets of REST has been reported to have clinical relevance in both breast cancer and glioblastoma. However it remains unclear how the REST signature works in neuroblastoma. Publicly available datasets were mined and bioinformatic approaches were used to investigate the utility of the REST signature in neuroblastoma with both preclinical and real patient data. The REST signature was found to be associated with drug sensitivity in neuroblastoma cell lines. Further, neuroblastoma patients with enhanced REST activity are significantly associated with higher clinical stages. Loss of heterozygosity on chromosome 11q23, which occurs in a large subset of high-risk neuroblastomas, tends to be correlated with high REST activity, with marginal significance. In conclusion, the REST signature has important implications for targeted therapy, and it is a prognostic factor in neuroblastoma patients.

Citing Articles

REST Is Restless in Neuronal and Non-Neuronal Virus Infections: An In Silico Analysis-Based Perspective.

Pillai V, Ravindran S, Krishna G, Abhinand C, Nelson-Sathi S, Veettil M Viruses. 2025; 17(2).

PMID: 40006989 PMC: 11860772. DOI: 10.3390/v17020234.

Regulatory non-coding somatic mutations as drivers of neuroblastoma.

Montella A, Tirelli M, Lasorsa V, Aievola V, Cerbone V, Manganiello R Br J Cancer. 2025; 132(5):469-480.

PMID: 39843641 PMC: 11876587. DOI: 10.1038/s41416-025-02939-0.

Protein Expression of NEK2, JMJD4, and REST in Clear Cell Renal Cell Carcinoma (ccRCC): Clinical, Pathological, and Prognostic Findings.

Elsayed W, Harb O, Alabiad M, Faraj Saad R, Anbaig A, Alorini M Iran J Pathol. 2023; 18(2):180-192.

PMID: 37600577 PMC: 10439757. DOI: 10.30699/IJP.2023.1974154.3022.

REST in the Road Map of Brain Development.

Lam X, Maniam S, Cheah P, Ling K Cell Mol Neurobiol. 2023; 43(7):3417-3433.

PMID: 37517069 PMC: 11410019. DOI: 10.1007/s10571-023-01394-w.

CRISPR/Cas9-based genome-wide screening of the deubiquitinase subfamily identifies USP3 as a protein stabilizer of REST blocking neuronal differentiation and promotes neuroblastoma tumorigenesis.

Karapurkar J, Kim M, Colaco J, Suresh B, Sarodaya N, Kim D J Exp Clin Cancer Res. 2023; 42(1):121.

PMID: 37170124 PMC: 10176696. DOI: 10.1186/s13046-023-02694-1.

References

Wagoner M, Roopra A . A REST derived gene signature stratifies glioblastomas into chemotherapy resistant and responsive disease. BMC Genomics. 2012; 13:686. PMC: 3545737. DOI: 10.1186/1471-2164-13-686. View

Fuller G, Su X, Price R, Cohen Z, Lang F, Sawaya R . Many human medulloblastoma tumors overexpress repressor element-1 silencing transcription (REST)/neuron-restrictive silencer factor, which can be functionally countered by REST-VP16. Mol Cancer Ther. 2005; 4(3):343-9. DOI: 10.1158/1535-7163.MCT-04-0228. View

Cohn S, Tweddle D . MYCN amplification remains prognostically strong 20 years after its "clinical debut". Eur J Cancer. 2004; 40(18):2639-42. DOI: 10.1016/j.ejca.2004.07.025. View

Krizkova S, Fabrik I, Huska D, Adam V, Babula P, Hrabeta J . An adsorptive transfer technique coupled with brdicka reaction to reveal the importance of metallothionein in chemotherapy with platinum based cytostatics. Int J Mol Sci. 2011; 11(12):4826-42. PMC: 3100849. DOI: 10.3390/ijms11124826. View

Tivnan A, Zhao J, Johns T, Day B, Stringer B, Boyd A . The tumor suppressor microRNA, miR-124a, is regulated by epigenetic silencing and by the transcriptional factor, REST in glioblastoma. Tumour Biol. 2013; 35(2):1459-65. DOI: 10.1007/s13277-013-1200-6. View

Pounds S, Morris S . Estimating the occurrence of false positives and false negatives in microarray studies by approximating and partitioning the empirical distribution of p-values. Bioinformatics. 2003; 19(10):1236-42. DOI: 10.1093/bioinformatics/btg148. View

Stallings R, Foley N, Bryan K, Buckley P, Bray I . Therapeutic targeting of miRNAs in neuroblastoma. Expert Opin Ther Targets. 2010; 14(9):951-62. DOI: 10.1517/14728222.2010.510136. View

Donev R, Gray L, Sivasankar B, Hughes T, van den Berg C, Morgan B . Modulation of CD59 expression by restrictive silencer factor-derived peptides in cancer immunotherapy for neuroblastoma. Cancer Res. 2008; 68(14):5979-87. PMC: 2475646. DOI: 10.1158/0008-5472.CAN-07-6828. View

Guo C, White P, Weiss M, Hogarty M, Thompson P, Stram D . Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas. Oncogene. 1999; 18(35):4948-57. DOI: 10.1038/sj.onc.1202887. View

10.

Schipper M, van Duinen S, Taphoorn M, Kloet A, Walchenbach R, Wiggenraad R . Cerebral ganglioneuroblastoma of adult onset: two patients and a review of the literature. Clin Neurol Neurosurg. 2012; 114(6):529-34. DOI: 10.1016/j.clineuro.2012.03.015. View

11.

Wang Q, Diskin S, Rappaport E, Attiyeh E, Mosse Y, Shue D . Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number. Cancer Res. 2006; 66(12):6050-62. DOI: 10.1158/0008-5472.CAN-05-4618. View

12.

Taylor P, Fangusaro J, Rajaram V, Goldman S, Helenowski I, MacDonald T . REST is a novel prognostic factor and therapeutic target for medulloblastoma. Mol Cancer Ther. 2012; 11(8):1713-1723. PMC: 3763747. DOI: 10.1158/1535-7163.MCT-11-0990. View

13.

Brodeur G, Seeger R, Schwab M, Varmus H, Bishop J . Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science. 1984; 224(4653):1121-4. DOI: 10.1126/science.6719137. View

14.

Santo E, Ebus M, Koster J, Schulte J, Lakeman A, van Sluis P . Oncogenic activation of FOXR1 by 11q23 intrachromosomal deletion-fusions in neuroblastoma. Oncogene. 2011; 31(12):1571-81. DOI: 10.1038/onc.2011.344. View

15.

Bell E, Chen L, Liu T, Marshall G, Lunec J, Tweddle D . MYCN oncoprotein targets and their therapeutic potential. Cancer Lett. 2010; 293(2):144-57. DOI: 10.1016/j.canlet.2010.01.015. View

16.

Zirath H, Frenzel A, Oliynyk G, Segerstrom L, Westermark U, Larsson K . MYC inhibition induces metabolic changes leading to accumulation of lipid droplets in tumor cells. Proc Natl Acad Sci U S A. 2013; 110(25):10258-63. PMC: 3690852. DOI: 10.1073/pnas.1222404110. View

17.

Li H, Jiang F, Shi P, Zhang T, Liu X, Lin X . In vitro reprogramming of rat bone marrow-derived mesenchymal stem cells into insulin-producing cells by genetically manipulating negative and positive regulators. Biochem Biophys Res Commun. 2012; 420(4):793-8. DOI: 10.1016/j.bbrc.2012.03.076. View

18.

Kamal M, Sathyan P, Singh S, Zinn P, Marisetty A, Liang S . REST regulates oncogenic properties of glioblastoma stem cells. Stem Cells. 2012; 30(3):405-14. PMC: 4039365. DOI: 10.1002/stem.1020. View

19.

Hsu D, Agarwal S, Benham A, Coarfa C, Trahan D, Chen Z . G-CSF receptor positive neuroblastoma subpopulations are enriched in chemotherapy-resistant or relapsed tumors and are highly tumorigenic. Cancer Res. 2013; 73(13):4134-46. PMC: 4298227. DOI: 10.1158/0008-5472.CAN-12-4056. View

20.

Soldati C, Bithell A, Johnston C, Wong K, Teng S, Beglopoulos V . Repressor element 1 silencing transcription factor couples loss of pluripotency with neural induction and neural differentiation. Stem Cells. 2011; 30(3):425-34. DOI: 10.1002/stem.1004. View